Article Text

other Versions

PDF
An open-label study of zoledronic acid (Aclasta 5 mg iv) in the treatment of ankylosing spondylitis
  1. G P R Clunie1,
  2. A Ginawi1,
  3. P O'Conner2,
  4. P W Bearcroft3,
  5. S J Garber4,
  6. S Bhagat1,
  7. A Grainger2,
  8. J S H Gaston5
  1. 1Department of Rheumatology, Addenbrooke's Hospital, Cambridge University NHS Foundation Trust, Cambridge, UK
  2. 2NIHR Leeds Biomedical Medical Research Unit, Chapel Allerton Hospital, Leeds Teaching Hospitals Trust, Leeds, UK
  3. 3Department of Diagnostic Imaging, Addenbrooke's Hospital, Cambridge University NHS Foundation Trust, Cambridge, UK
  4. 4Department of Radiology, The Ipswich Hospital NHS Trust, Ipswich, UK
  5. 5Department of Medicine, Cambridge University School of Medicine, Addenbrookes Hospital, Cambridge, UK
  1. Correspondence to Dr GPR Clunie, Department of Rheumatology, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0QQ, UK; gavin.clunie{at}doctors.org.uk

Statistics from Altmetric.com

Spinal lesions in ankylosing spondylitis (AS) include osteitis and spondylodiscitis—bone lesions characterised by high signal on T2w fat-suppressed or STIR magnetic resonance (MR) imaging.1 Pamidronate treats osteitis and improves spinal symptoms in non-steroidal anti-inflammatory drug (NSAID)-refractory AS,2 but treatment gains are modest. Zoledronic acid (Aclasta/Reclast; ZA) is more ‘potent’ than pamidronate,3 but it is unknown whether ZA improves osteitis in AS. We evaluated whether ZA reduces osteitis lesions in AS using an MR index of spinal osteitis4 previously shown to correlate with, and be responsive to treatment of, AS disease activity measures.5

Patients with AS (modified New York criteria,6 >18 years old, Bath AS Disease Activity Index (BASDAI) ≥4.15, anti-tumour necrosis factor α (anti-TNFα)-naive) were recruited based on having osteitis in two or more discovertebral units (DVUs; SPARCC definition …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles